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population with asthma. RESULTS: We found 18 articles that
met the inclusion criteria; three were validation studies and the
remaining were observational studies or clinical trials. All three
domains of the SGRQ are internally consistent and reliable with
ICC of at least 0.70 for individual domains and greater than 0.90
for total score. Convergence and discriminate validity were seen
with two of three domains and dyspnea grade, six-minute walk
distance, and other HRQoL instruments. Face and content valid-
ity were demonstrated. SGRQ was able to discriminate between
patients with varying levels of symptoms, FEV1, self-reported
healthcare utilization services, asthma control problems, and
HRQoL. Responsiveness to change, however, is not well-
established for SGRQ despite a reported minimally important
difference of 3.9-unit change, which may be due partly to a
paucity of studies using SGRQ in this population. CONCLU-
SIONS: Our ﬁndings suggest SGRQ has face, content, and con-
struct validity. It is able to discriminate between different groups
of asthma patients, and may be useful in facilitating asthma
resource allocation. Further research is needed to determine its
responsiveness to change.
PAS11
PROPENSITY SCORE MATCHING WITH MORE 
THAN TWO CATEGORIES
Baser O
Thomson-Medstat, Ann Arbor, MI, USA
OBJECTIVE: We applied the extension of propensity score
methodology that allows for estimation of average causal effects
with multi-valued treatment. METHODS: The methodology
requires three steps: 1. Estimating propensity score with multin-
omial or nested logit 2. Estimating the conditional expectation
and 3. estimate average respond treatment by calculating average
of conditional expectation averaged over the distribution of the
pre-treatment variables. RESULTS: The Market Scan private
insurance data base was used in this study which based upon
asthma individuals whose health care was provided under a
variety of fee-for-service (FFS), fully capitated and partially cap-
itated health plans, including exclusive provider organizations,
indemnity plans. Treatment is divided into three categories: a)
controller only; b) reliver only; and c) reliever and controller.
These three categories is matched with control group using mul-
tionomial logit. Pre-period demographic and clinical factors are
used as a covariate. Conditional expectations are calculated and
applied as a weight to estimate average treatment effect among
asthma patients. Reliever and Controller patients have 
the highest treatment effect whereas controller only patients have
the lowest effect. CONCLUSION: Multi-valued treatment is
common in pharmacoeconomical research and extension of
propensity score matching to cover multi-valued treatment is
straightforward and easy to apply.
ASTHMA—Patient Reported Outcomes
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TREATMENT PERSISTENCE AND COMPLIANCE WITH
MEDICATIONS FOR ASTHMA AND CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Cramer JA1, Bradley-Kennedy C2, Scalera A3
1Yale University School of Medicine, West Haven, CT, USA,
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OBJECTIVE: To assess the patterns of persistence with various
classes of inhaled medications (i.e., beta agonist, anticholinergic,
and glucocorticoid) medications used to treat asthma and
chronic obstructive pulmonary disease (COPD). METHODS:
Pharmacy claims data were analyzed for persistence with inhaled
treatment (time to discontinuation) using a 60-day gap to deﬁne
discontinuation. Compliance, deﬁned as the percentage of days
with doses available divided by days to last reﬁll, also was
assessed. Patients were grouped as naïve (no inhaled medication
in the previous year) or experienced (previous or current treat-
ment), and by age (18–65, 65+ years). Medications included:
ipratropium, ipratropium + salbutamol, formoterol, formoterol
+ budesonide, salmeterol, salmeterol + ﬂuticasone, and
tiotropium. RESULTS: The database included 31,368 patients
prescribed one of these medications (4,888 naïve, 26,480 expe-
rienced). Based on a 60-day lapse in reﬁll, only 15–63% of
patients continued on the index drug for more than 6 months,
further decreasing to 7–53% at 12 months, and 5–47% at 18
months. At 12 months, patients taking tiotropium had signiﬁ-
cantly longer persistence rates compared to that for other drugs
(53% versus 7–30%, all p < 0.0001), and fewer switches to alter-
native medications. Naïve patients had signiﬁcantly shorter treat-
ment persistence than experienced patients for all drugs (all p <
0.0001), including tiotropium (27% versus 55%, p < 0.0001).
Compliance rates were similar for all drugs (i.e., 76%–94%) but
highest for tiotropium. CONCLUSIONS: These data demon-
strated that 1) persistence with inhaled treatment for asthma and
COPD was low overall (despite the generous 60-day allowance
to reﬁll), but patients stayed on treatment with tiotropium sig-
niﬁcantly longer than with other medications, and 2) patients
naïve to these classes of inhaled treatment had shorter treatment
persistence than experienced patients.
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Asthma is a chronic inﬂammatory disorder of the lungs and has
a signiﬁcant impact on morbidity, mortality, and health-related
quality of life (HRQL). Asthma also impacts indirect costs result-
ing from losses in workplace productivity. OBJECTIVE: To
examine the association of medication adherence with workplace
productivity and HRQL in patients with asthma in a state health
insurance program. METHODS: The diagnosis of asthma was
identiﬁed from medical claims data of state employees between
18 and 65 years of age who obtained healthcare beneﬁts from a
state health insurance program from July 2001 through June
2003. A three-part survey was mailed to these patients to
measure HRQL, workplace productivity, (absenteeism [time lost
from work] and presenteeism [reduced productivity at work]),
and self-reported medication adherence. The survey consisted of
the St. George’s Respiratory Questionnaire, the Workplace Pro-
ductivity Short Inventory, and the Morisky Adherence Scale. Pro-
ductivity losses were translated into dollar values by using
previously published metrics (employer perspective). The associ-
ation between self-reported medication adherence and HRQL
and productivity was measured using multivariate regression
analyses. RESULTS: The response rate was 25.1% (385/1493).
The mean HRQL total summary score was 33.2 ± 19.9 units,
with the symptoms domain having the worst HRQL scores (49.3
± 21.4 units), followed by the activity (39.6 ± 26.6) and impacts
(24.6 ± 19.1) domains. 39% of the participants reported them-
selves as “high” adherent, 19% reported themselves as
“medium” adherent, and 42% as “low” adherent. Asthma
resulted in productivity losses of $597 ± $1024 (absenteeism)
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and $658 ± $1808 (presenteeism) per enrollee per year. Morisky-
based adherence was not a signiﬁcant predictor of HRQL or pro-
ductivity in the multivariate models. CONCLUSIONS: Asthma
was associated with HRQL detriments and workplace produc-
tivity losses. Medication adherence continues to be a problem
among asthma patients.
CANCER—Clinical Outcomes Studies
PCN1
ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG
CANCER ADJUVANT TREATMENTS IN PRACTICE USING
INSTRUMENTAL VARIABLE METHODS
Brooks JM1, Chrischilles EA2, Chen-Hardee S1, Cho E1, Scott SD3
1University of Iowa, Iowa City, IA, USA, 2Univerisity of Iowa, Iowa City,
IA, USA, 3University of Newcastle, Newcastle, Australia
OBJECTIVES: Recent randomized controlled trials demon-
strated the efﬁcacy of adjuvant chemotherapy for certain patients
with early-stage lung cancer (Winton et al. NEJM 2005) while
the efﬁcacy of adjuvant radiation therapy hasn’t been determined
in clinical trials for these patients. Both treatments have been
used in practice for years and it isn’t clear whether patient sur-
vival beneﬁts are available by expanding treatment rates.
OBJECTIVE: estimate the effectiveness of these treatments in
practice, assess whether survival beneﬁts are available from
expanding treatment rates. It has been suggested that instru-
mental variable estimates on observational data provide such an
interpretation (McClellan et al. JAMA, 1994). METHODS:
Apply instrumental variable (IV) methods to 7614 early-stage
lung cancer patients that received surgery from the SEER-
Medicare databases (1991–1999) to assess the effectiveness of
each adjuvant treatment. Instruments included area-level
Herﬁndahl indices of patient concentration across providers and
area-level treatment rates across time. Covariates included stage,
grade, tumor site, age, gender, and race. RESULTS: Using IV
methods, we found that our instruments explained a statistically
signiﬁcant portion of the variation in adjuvant treatment use.
Using the treatment variation stemming from the instruments,
we found the adjuvant chemotherapy had a positive effect on
three-year patient survival (p < 0.05) while adjuvant radiation
therapy didn’t. Using standard risk-adjustment models leaving
residual confounding in spite of controlling for measured covari-
ates, both adjuvant chemotherapy and adjuvant radiation
therapy had statistically signiﬁcant negative relationships with
three-year patient survival (p < 0.05). CONCLUSION: Using IV
methods provides estimates of effects of treatments in practice,
suggesting survival rates would increase if adjuvant chemother-
apy rates increased for early-stage lung cancer patients. No sur-
vival gains appear available from expanding adjuvant radiation
therapy rates. The IV results contrast the negative “treatment
effects” in standard risk-adjustment models, suggesting that
providers recommended adjuvant treatments to patients with
higher unmeasured severity levels.
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EFFECTIVENESS OF A COMMUNITY—BASED PROSTATE
CANCER EDUCATION KIOSK FOR AFRICAN AMERICAN MEN:
ANALYSES OF COST, SATISFACTION, QUALITY, KNOWLEDGE,
AND INTENTION VARIABLES
Young S, Odedina F,Warrick C
Florida A&M University,Tallahassee, FL, USA
OBJECTIVES: The Healthy People 2010 goal for the nation con-
cerning prostate cancer is to reduce prostate cancer death rate to
28.8 deaths per 100,000 males by 2010. The reported death rate
for African-American men in 2002 was 62.0 per 100,000 males
and for Caucasian men 25.7 per 100,000 males. Based on this
statistic, Caucasian men already fare better than the projected
goal for 2010 while African American (AA) men have a long way
to go to achieve this goal. Prostate cancer education and aware-
ness is very important to eliminate the disparities experienced by
AA men. Thus, the purpose of this study is to evaluate the effec-
tiveness of the prostate cancer education kiosk (PCEK).
METHODS: Participants were adult AAs who are employees of
an HBCU institution. A structured survey instrument assessing
participants’ demographics and prostate cancer knowledge was
employed for the study. Data collection involved three steps: 1)
completion of survey before use of kiosk {pre-test}, 2) use of
kiosk by participants {post-test}, and 3) completion of survey
after use of kiosk {post-test}. RESULTS: Of the 100 participants,
most were men (78%), single (53%), had at least a college degree
(52%), and between 40–49 years (58%). Men’s score on both
the pre-test and post-test knowledge scores were higher than
women. PCEK was found to signiﬁcantly improve participants’
knowledge. The post-test knowledge score of participants
(89.42%) was higher than the pre-test knowledge score of par-
ticipants (67.92%). CONCLUSION: PCEK offers an effective
method to educate AA men about prostate cancer. Future studies
should explore the cost-effectiveness of touch screen computers
such as PCEK in educating the AA community on diverse health
issues.
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AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR
DELAYED NAUSEA AND VOMITING USING ELECTRONIC
MEDICAL RECORDS
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OBJECTIVES: Delayed chemotherapy-induced nausea and vom-
iting (CINV) can increase healthcare utilization and decrease
patient quality of life. While reports of delayed CINV range from
40–60% with moderately to highly emetogenic regimens, little
information is available on utilization of care as a result. To
determine the frequency of outpatient service utilization associ-
ated with CINV between 24–120 hours following chemotherapy
administration during cycles 1–5. METHODS: A retrospective
observational design of US Oncology nation-wide iKnowMed
electronic medical records (EMR) was employed. The cohort for
analysis included patients from four practices in separate 
states receiving chemotherapy between August 2004 and 
April 2005. Chemotherapy regimens included one or more of 
the following ﬁve drugs: carboplatin, cisplatin, oxaliplatin, 
doxorubicin, cyclophosphamide. Failure was deﬁned as one 
or more of the following events between 24–120 hours 
following chemotherapy: phone encounters with documentation
of CINV; non-chemotherapy ofﬁce visits for hydration, IV 
anti-emetic administration, and/or documentation of CINV; 
oral anti-emetic orders between 24–120 hours. RESULTS:
A total of 691 patients were identiﬁed as receiving target
chemotherapies during cycles 1–5. Mean (std) age was 61 
(13) years, and 62% were female. Twenty-six percent had 
breast cancer, 26% lung, 10% colorectal, and 8% lymphoma. 
In cycle 1, the rate of failure was 6.7%; in cycle 2, 5.9%; in cycle
3, 5%; in cycle 4, 5.3%; and in cycle 5, 4.0%. All patients
received one or more IV anti-emetic on Day 1 of each cycle.
CONCLUSION: The rates reported in this cohort of patients
from a nation-wide EMR database indicate that while many
patients may experience some degree of CINV during days 2–5
of chemotherapy, only a small percentage receive outpatient
clinic care as a result.
